| Titre : | Deprescribing in France: a multi-stakeholder survey to inform public debate |
| Auteurs : | Sergio Oliveira Formoso ; Ecole des hautes études en santé publique (EHESP) (Rennes, FRA) |
| Type de document : | Mémoire |
| Année de publication : | 2025 |
| Description : | 61p. |
| Langues: | Anglais |
| Classement : | MPH/ (Mémoires MPH à partir de 2024) |
| Mots-clés : | Prescription ; Médicament ; Consommation pharmaceutique ; Médicament inapproprié ; Politique santé ; France |
| Résumé : |
Background: In France, the ageing population and rising multimorbidity led to polypharmacy and inappropriate medication use. This poses significant health, economic, and environmental challenges for the country. Deprescribing is an appropriate solution to tackle this issue, but France lacks a national deprescribing framework and faces a series of implementation barriers shared across stakeholders.
Objective: This study explored stakeholder attitudes, barriers, and facilitators towards deprescribing in France, to understand where alignment is possible to move deprescribing forward. It also assessed stakeholders’ perceptions around the clinical, economic, and environmental impacts of deprescribing, to inform novel policy development and implementation. Methods: An exploratory survey gathered perspectives from key stakeholders (healthcare professionals, patients, academia, policymakers, and the pharmaceutical industry). A 32% response rate was obtained. Consensus and agreement were analysed using an adapted Policy Delphi method. Results: Significant gaps exist around knowledge and training. Barriers for deprescribing are shared between countries and healthcare systems. Stakeholders highlighted patient resistance, communication and interprofessional/intersectoral collaboration, low availability and access to resources (time, human, information), misaligned policy, and outdated regulatory frameworks as important barriers. Regardless, deprescribing is seen across stakeholders as an opportunity to improve patient safety and quality of life, as well as a safe practice with a positive impact in addressing the economic burden of the healthcare system and improving the environmental sustainability of the healthcare system. Conclusions: This study provides critical evidence for designing stakeholder-responsive deprescribing policies in France. While stakeholders recognise the multifaceted benefits of deprescribing, implementation barriers and multistakeholder resistance limit innovation in this area and its widespread use as routine clinical practice. |
| Diplôme : | Master MPH of public health |
| Plan de classement simplifié : | Master of Public Health - master international de Santé Publique (MPH) |
| En ligne : | https://documentation.ehesp.fr/memoires/2025/mph/sergio_oliveira_formoso.pdf |
Documents numériques (1)
Full text URL |
